{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:52:24Z","timestamp":1794243144390,"version":"4.9.0"},"reference-count":31,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the long-term safety outcomes of recombinant human growth hormone (rhGH) administered to Korean pediatric patients with growth disorders, including growth hormone deficiency, Turner syndrome, idiopathic short stature, small for gestational age, chronic kidney disease, and Prader\u2013Willi syndrome, using the 10-year interim data from the nationwide LG Growth Study registry in the Republic of Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a prospective, multicenter, observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This interim analysis included 5,040 patients from 96 centers, representing 19,878 patient-years of treatment between November 2011 and December 2022. Although the registry spans 10 years, follow-up was limited to periods of active GH treatment and, therefore, varied across patients. Patients received daily or weekly rhGH. Adverse events (AEs), adverse drug reactions (ADRs), serious AEs (SAEs), and serious ADRs (SADRs) were recorded and compared with international registry data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, AEs occurred in 34.2% of patients, ADRs in 7.0%, SAEs in 3.2%, and SADRs in 0.3%. The most frequent AE was scoliosis (1.6%), followed by headache (0.8%) and injection site pain (0.5%). Three malignant neoplasms were reported, yielding a standardized incidence ratio of 1.1 (95% confidence interval: 0.21\u20132.69), comparable to expected national rates. Craniopharyngioma recurrence occurred in 14.3% of affected patients, consistent with international data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over the 10 years, rhGH therapy in Korean pediatric patients demonstrated a low incidence of ADRs and SADRs, with malignancy and tumor recurrence rates similar to those in global registries. These findings support the long-term safety of rhGH for pediatric growth disorders, with continued surveillance warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Using 10 years of real-world data from a pediatric registry, conducted in the Republic of Korea, this study provides one of the largest single-nation safety evaluations of rhGH therapy across multiple etiologies of short stature. The low incidence rates of ADRs and SADRs, in alignment with rates reported for other large-scale international registries, provide reassuring evidence of the safety of rhGH for clinicians and caregivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-26-0073","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:46:32Z","timestamp":1779119192000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-5069","authenticated-orcid":true,"given":"Yoo-Mi","family":"Kim","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jun","family":"Rhie","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Wook","family":"Chae","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-7443","authenticated-orcid":true,"given":"Jaehyun","family":"Kim","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ah","family":"Lee","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Sang","family":"Lee","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hee","family":"Hong","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Hye","family":"Kim","sequence":"additional","affiliation":[{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Bae","family":"Ahn","sequence":"additional","affiliation":[{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Jeon","sequence":"additional","affiliation":[{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-1134","authenticated-orcid":true,"given":"Choong Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2026070714131958700_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone \u2013 past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026070714131958700_bib2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1210\/clinem\/dgab080","article-title":"Long-term safety of growth hormone treatment in childhood: two large observational studies: nordinet IOS and ANSWER","volume":"106","author":"S\u00e4vendahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pediatr"},{"key":"2026070714131958700_bib4","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","article-title":"Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort","volume":"107","author":"Maghnie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/jc.2018-01189","article-title":"Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/08035250600577889","article-title":"Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database)","volume":"95","author":"Darendeliler","year":"2006","journal-title":"Acta Paediatr"},{"key":"2026070714131958700_bib7","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1210\/clinem\/dgae834","article-title":"Long-acting growth hormone therapy in pediatric growth hormone deficiency: a consensus statement","volume":"110","author":"Maniatis","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6065\/apem.2448258.129","article-title":"Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations","volume":"30","author":"Maniatis","year":"2025","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib9","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/clinem\/dgad394","article-title":"Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib10","doi-asserted-by":"crossref","first-page":"e2680","DOI":"10.1210\/clinem\/dgac217","article-title":"Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enlighten trial 2-year results","volume":"107","author":"Maniatis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216927","article-title":"Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG growth study","volume":"14","author":"Rhie","year":"2019","journal-title":"PLoS One"},{"key":"2026070714131958700_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6065\/apem.2018.23.1.43","article-title":"Design of the long-term observational cohort study with recombinant human growth hormone in Korean children: LG Growth Study","volume":"23","author":"Chung","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib13","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0218","article-title":"Impact of COVID-19 on growth hormone therapy efficacy in pediatric patients with short stature","volume":"14","author":"Kim","year":"2025","journal-title":"Endocr Connect"},{"key":"2026070714131958700_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.6065\/apem.2448070.035","article-title":"Pituitary abnormalities in patients with pediatric growth hormone deficiency in a single tertiary center","volume":"29","author":"Jung","year":"2024","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.6065\/apem.2014.19.3.146","article-title":"New Korean reference for birth weight by gestational age and sex: data from the Korean Statistical Information Service (2008\u20132012)","volume":"19","author":"Lim","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinbiochem.2011.10.003","article-title":"Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents","volume":"45","author":"Hyun","year":"2012","journal-title":"Clin Biochem"},{"key":"2026070714131958700_bib17","article-title":"Annual report of cancer statistics in Korea in 2020","author":"Korea Central Cancer Registry, National Cancer Center","year":"2022"},{"key":"2026070714131958700_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone-A combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol"},{"key":"2026070714131958700_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1210\/clinem\/dgab746","article-title":"Approach to the patient: safety of growth hormone replacement in children and adolescents","volume":"107","author":"Bamba","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.6065\/apem.2142186.093","article-title":"The association between idiopathic scoliosis and growth hormone treatment in short children","volume":"27","author":"Park","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1515\/jpem-2020-0393","article-title":"Impact of growth hormone treatment on scoliosis development and progression: analysis of 1128 patients with idiopathic short stature","volume":"34","author":"Park","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"2026070714131958700_bib23","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1210\/jc.2018-01205","article-title":"GH therapy in childhood cancer survivors: a systematic review and meta-analysis","volume":"103","author":"Tamhane","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.745932","article-title":"Growth hormone deficiency and treatment in childhood cancer survivors","volume":"12","author":"Pollock","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070714131958700_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11102-025-01581-6","article-title":"The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis","volume":"28","author":"Pan","year":"2025","journal-title":"Pituitary"},{"key":"2026070714131958700_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070714131958700_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study","volume":"97","author":"Carel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2015-3951","article-title":"Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics","volume":"101","author":"Albertsson-Wikland","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714131958700_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of childhood growth hormone treatment with long-term cardiovascular morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2026070714131958700_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.6065\/apem.2244046.023","article-title":"The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma","volume":"28","author":"Park","year":"2023","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026070714131958700_bib31","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1210\/jc.2017-00214","article-title":"Mortality in children receiving growth hormone treatment of growth disorders: data from the genetics and neuroendocrinology of short stature international study","volume":"102","author":"Quigley","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/6\/EC-26-0073.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/6\/EC-26-0073.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0073\/521285\/ec-26-0073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0073\/521285\/ec-26-0073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:13:32Z","timestamp":1783448012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/6\/e260073\/77581\/Accumulated-safety-data-of-recombinant-human"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-26-0073","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"e260073"}}